Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
814
datasets available to search
ShareScore release 0.9.0
Dataset results
814 results for “pancreatic adenocarcinoma”
Standard Versus Extended Lymphadenectomy in Pancreatoduodenectomy for Patients With Pancreatic Head Adenocarcinoma
ClinicalTrials.gov study NCT02928081. IPD Sharing: NO. Countries: 1. Publications: 8.
Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2
ClinicalTrials.gov study NCT04935359. IPD Sharing: YES. Countries: 27. Publications: 0.
Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
ClinicalTrials.gov study NCT06790602. IPD Sharing: NO. Countries: 1. Publications: 1.
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
ClinicalTrials.gov study NCT06625320. IPD Sharing: Not stated. Countries: 7. Publications: 0.
Side Population in Pancreatic Ductal Adenocarcinoma (PDAC)
ClinicalTrials.gov study NCT00936104. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Anatomical-Clinical Base of Adenocarcinoma Pancreatic
ClinicalTrials.gov study NCT06128343. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Data from: Ultrasonic cavitation induces necrosis and impairs growth in three-dimensional models of pancreatic ductal adenocarcinoma
Introduction: Pancreatic ductal adenocarcinoma (PDAC) is a rapidly increasing cause of mortality whose dismal prognosis is mainly due to overwhelming chemoresistance. New therapeutic approaches include physical agents such as ultrasonic cavitation, but clinical applications require further insights in the mechanisms of cytotoxicity. Three dimensional in vitro culture models such as spheroids exploit realistic spatial, biochemical and cellular heterogeneity that may bridge some of the experimental gap between conventional in vitro and in vivo experiments. Purpose: to assess the feasibility and efficiency of inertial cavitation associated or not with chemotherapy, in a spheroid model of PDAC. Methods: we used DT66066 cells ,derived from a genetically-engineered murine PDAC, isolated from KPC-transgenic mice (LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1- Cre). Spheroids were obtained by either a standard centrifugation-based method, or by using a magnetic nano-shuttle method allowing the formation of spheroids within 24 hours and facilitating their handling. The spheroids were exposed to ultrasonic inertial cavitation in a specially designed setup. Four conditions were studied: control, gemcitabine alone , US cavitation alone , US cavitation + gemcitabine. Five US inertial cavitation indexes, corresponding to increased US intensities, were evaluated . The effectiveness of treatment was assessed after 24 hours with the following criteria: spheroid size (growth), ratio of phase S cells (proliferation), proportion of cells in apoptosis or necrosis (cellular mortality). These parameters were assessed by quantitative immunofluorescence techniques. Results: The 3D culture model presented excellent reproducibility. Eight or nine spheroids were analyzed for each condition. Cavitation induced a significant decrease in the size of spheroids , an effect significantly correlated to an increasing cavitation index (p < 0.0001). The treatment induced cell death whose predominant mechanism was necrosis (p < 0.0001). There was a tendency to a synergistic effect of US cavitation and gemcitabine at 5μM concentration, however significant in only one of the cavitation indexes used (p = 0. 013). Conclusion: Ultrasonic inertial cavitation induced a significant reduction of tumor growth in a spheroid model of PDAC., with necrosis rather than apoptosis as a Cell dominant mechanism of cell death. More investigations are needed to understand the potential role of inertial cavitation in overcoming chemoresistance.
postoperative survival of patients with pancreatic ductal adenocarcinoma
<p>Postoperative information of pancreatic cancer patients</p>
CXCL12 expression predicts survival in Radically Resected (R0) primary pancreatic adenocarcinoma
<p>PDAC CXCR4 CXCL12 CXCR7 PD-L1 dataset</p>
The Impact Of Tissue Micro-RNA Profile From EUS-FNA In Pancreatic Adenocarcinoma
ClinicalTrials.gov study NCT04765410. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.
ClinicalTrials.gov study NCT03767582. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
ClinicalTrials.gov study NCT02101021. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma
ClinicalTrials.gov study NCT01206296. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma
ClinicalTrials.gov study NCT05525286. IPD Sharing: NO. Countries: 5. Publications: 0.
Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma
ClinicalTrials.gov study NCT01431794. IPD Sharing: NO. Countries: 1. Publications: 0.
Palliative Stereotactic Radiation for Pancreatic or Periampullary Adenocarcinoma
ClinicalTrials.gov study NCT01781728. IPD Sharing: NO. Countries: 1. Publications: 0.
EndoTAG-1+GEM vs GEM in Patients With Locally Advanced/Metastatic Pancreatic Adenocarcinoma Failed on FOLFIRINOX
ClinicalTrials.gov study NCT03126435. IPD Sharing: Not stated. Countries: 7. Publications: 0.
Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
ClinicalTrials.gov study NCT04329949. IPD Sharing: NO. Countries: 1. Publications: 0.
Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma
ClinicalTrials.gov study NCT03099265. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection
ClinicalTrials.gov study NCT02241187. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.